Does Scripps Health Cover Prolia?

What Is Prolia and Why Does Coverage Complexity Arise?

Prolia is a RANK ligand inhibitor that suppresses osteoclast activity, slowing bone resorption in patients with osteoporosis and other bone-loss conditions. The FDA approved denosumab 60 mg (Prolia) in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later expanded indications include men with osteoporosis, glucocorticoid-induced bone loss, and bone loss associated with hormone-ablation therapy in cancer patients [1].

Coverage complexity arises from its cost and mechanism of administration. A single injection lists at roughly $1,000 to $1,400 per dose in 2024, which places it firmly in specialty or medical-benefit territory for virtually every payer. Unlike oral bisphosphonates, which pharmacies dispense and patients self-administer, Prolia is typically administered in a clinician's office or infusion center. That distinction matters enormously for billing: most commercial and government payers process Prolia under the medical benefit (think physician-office claims) rather than the pharmacy benefit, which shifts the prior-authorization pathway and the relevant formulary tier.

Scripps Health operates both a health system and affiliated insurance products through Scripps Health Plan. Patients seen within the Scripps network may access Prolia through their Scripps Health Plan coverage, through Medicare Advantage plans that contract with Scripps, or through separate commercial plans that have network agreements with Scripps providers. Each coverage vehicle has its own formulary and prior-authorization rules, which is why two patients sitting in the same Scripps rheumatology clinic may receive different coverage decisions on the same day.

The FREEDOM trial (N=7,868) established the clinical case for Prolia, showing a 68% reduction in new vertebral fracture risk over 36 months compared with placebo (P<0.0001) [2]. That level of evidence is part of why major guidelines recommend it, but a drug being clinically indicated and a payer covering it are two separate questions.

How Scripps Health Plan Structures Prolia Coverage

Scripps Health Plan, the integrated plan serving San Diego-area members, follows standard managed-care coverage logic for specialty injectables. Prolia coverage typically sits under the medical benefit, not the pharmacy benefit. That means your Scripps-affiliated primary care physician or specialist submits a prior-authorization request through the medical-management pathway, not through a specialty pharmacy channel.

The core coverage criteria Scripps Health Plan and most affiliated plans apply include all of the following:

Confirmed osteoporosis diagnosis. A DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip qualifies. A documented low-trauma (fragility) fracture in a patient over 50 also qualifies, sometimes even without a DXA result at that threshold.

Documented step therapy. The large majority of commercial plans, including those affiliated with Scripps, require a trial of at least one oral bisphosphonate (alendronate, risedronate) or intravenous bisphosphonate (zoledronic acid) before approving Prolia. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines note that bisphosphonates remain first-line agents for most patients due to long-term safety data and cost, while denosumab is recommended for patients who cannot tolerate or fail bisphosphonate therapy, or who have specific clinical features such as severe renal impairment [3].

Prescriber type. Prior-authorization forms for Prolia generally require the prescribing clinician to be a specialist in rheumatology, endocrinology, or oncology, or to provide documentation justifying a primary-care prescription.

Duration of authorization. Approvals are typically granted for 12 months (two injections). Renewal requires re-authorization with updated DXA results or clinical notes documenting continued benefit.

Medicare Coverage of Prolia Through Scripps-Affiliated Plans

Many Scripps patients are Medicare beneficiaries, either in Original Medicare or a Medicare Advantage plan. Understanding which applies to you changes the financial math significantly.

Original Medicare (Part B). Prolia administered in a physician's office or outpatient hospital setting is billed under Medicare Part B as a physician-administered drug. Under Part B, Medicare pays 80% of the allowed amount after the Part B deductible ($240 in 2024), and the patient is responsible for the remaining 20%. Without a Medigap supplement, that 20% can still reach $200 to $280 per injection. Scripps-employed physicians who accept Medicare assignment will bill the plan directly.

Medicare Advantage plans with Scripps network participation. Several Medicare Advantage plans operate within the Scripps provider network in San Diego County. These plans set their own cost-sharing structures, and some offer lower specialty-drug cost-sharing than Original Medicare. Coverage criteria for Prolia under Medicare Advantage plans largely mirror CMS guidance, which recognizes denosumab as a medically necessary treatment for osteoporosis meeting FRAX or DXA thresholds consistent with National Osteoporosis Foundation recommendations [4].

The Centers for Medicare and Medicaid Services issued guidance clarifying that for Medicare Part D, injectable drugs administered by a health professional are generally covered under Part B, not Part D. Patients should confirm with their specific plan which benefit applies [5].

Prior Authorization: What to Expect and How to Build a Strong Request

Prior authorization for Prolia is the step where most denials occur, and most denials are avoidable with complete documentation. The authorization request submitted to a Scripps-affiliated plan or any other payer should include all of the following elements.

First, provide the ICD-10 code precisely. M81.0 (age-related osteoporosis without current pathological fracture) or M80.00XA (age-related osteoporosis with current pathological fracture, initial encounter) are the two most common. Using an imprecise code is one of the fastest paths to a technical denial.

Second, include the most recent DXA report with T-scores at all three sites. If the report is older than two years, most plans will request a new scan before approving.

Third, document bisphosphonate step therapy explicitly. A note that simply says "patient tried alendronate" is insufficient. The note should specify the agent, dose, duration of trial, and the reason for discontinuation or inadequacy (gastrointestinal intolerance, esophageal disease, renal insufficiency, persistent bone loss despite adherence, or atypical femur fracture concern). A 2021 analysis in Osteoporosis International found that step-therapy requirements delay appropriate osteoporosis treatment by a median of 4.3 months and increase fracture risk for high-risk patients [6].

Fourth, include the prescribing physician's clinical rationale for Prolia specifically, including any published guideline citation (AACE, NOF, Endocrine Society) supporting the choice.

The HealthRX clinical team has assembled the following decision framework for evaluating Prolia prior-authorization requests. Patients who can check all four boxes have the strongest approval profiles: (1) DXA T-score <-2.5 or fragility fracture documented in chart; (2) at least one bisphosphonate trial of 12 months or documented contraindication; (3) specialist or specialist-supervised prescriber; (4) FRAX 10-year major osteoporotic fracture probability greater than 20% or hip fracture probability greater than 3%. Patients meeting all four criteria rarely face sustained denials.

What Happens After a Denial

A first-level denial of Prolia coverage is not final. Federal law under the ACA and CMS rules for Medicare Advantage require payers to offer at least one internal appeal and, in most states, an independent external review.

Internal appeal. Submit a written appeal within the timeframe specified on the denial notice (typically 60 days for commercial plans, 60 days for Medicare Advantage Part C). Include any clinical literature your prescriber can provide. The FREEDOM trial data, the AACE 2020 guidelines, and any recent FRAX calculation printed from the official WHO FRAX tool are all useful attachments [7].

Peer-to-peer review. Most plans, including those affiliated with Scripps Health, allow the prescribing physician to request a peer-to-peer conversation with the plan's medical reviewer. This call frequently reverses denials. Physicians should request this immediately upon receiving a denial, because the peer-to-peer window closes quickly (often within 72 hours of the denial date).

External review. If the internal appeal fails, California patients (where Scripps Health is headquartered) may request an independent medical review through the California Department of Managed Health Care (DMHC). The DMHC external review overturns health plan denials in favor of the patient roughly 40% of the time across all drug categories.

Exceptions based on medical necessity. Patients with a documented contraindication to bisphosphonates (e.g., eGFR <35 mL/min, history of esophageal stricture or achalasia, atypical femoral fracture on bisphosphonate therapy) can request a medical-necessity exception that bypasses step-therapy requirements. The National Kidney Foundation and KDIGO guidelines note that bisphosphonates carry increased fracture risk monitoring requirements in patients with eGFR <30 mL/min, supporting denosumab as a preferred alternative in that population [8].

Cost Assistance Programs for Patients Facing Coverage Gaps

Even when coverage is approved, cost-sharing can be significant. Several programs reduce patient out-of-pocket costs.

Amgen FIRST STEP program. Amgen (Prolia's manufacturer) offers the FIRST STEP patient support program, which provides Prolia at no cost for eligible uninsured or underinsured patients who meet income criteria (generally household income at or below 500% of the federal poverty level). Eligible patients receive up to 12 free doses annually.

Amgen copay card. For commercially insured patients who do not qualify for Medicare or Medicaid, the Amgen copay card can reduce out-of-pocket cost to as low as $0 per dose per year. The card does not apply to government-funded plans (Medicare, Medicaid, TRICARE, VA).

340B pricing at Scripps Health facilities. Scripps Health participates in the federal 340B Drug Pricing Program, which allows qualifying outpatient facilities to purchase drugs at substantially reduced prices. Patients who receive Prolia at a Scripps 340B-covered outpatient clinic may see lower acquisition costs passed through to their bills. Ask the billing department whether the specific clinic is a 340B covered entity.

California Medicaid (Medi-Cal). Medi-Cal covers Prolia for qualifying low-income California residents, subject to the Medi-Cal formulary criteria that largely mirror the clinical thresholds described above.

Alternatives if Prolia Coverage Is Denied

If a Prolia authorization denial cannot be reversed after appeals, clinicians and patients have several effective alternatives, some of which face fewer coverage barriers.

Zoledronic acid (Reclast). Given as a single annual intravenous infusion, zoledronic acid reduces vertebral fracture risk by 70% over three years, as shown in the HORIZON Key Fracture Trial (N=7,765) [9]. It is covered under Medicare Part B as a physician-administered drug and typically has more permissive prior-authorization requirements than Prolia.

Alendronate (generic). Generic alendronate (70 mg weekly) costs under $15 per month at most pharmacies and faces minimal prior-authorization barriers. For patients who can tolerate oral bisphosphonate therapy, it remains an entirely reasonable first step.

Romosozumab (Evenity). For very high-risk patients, romosozumab (a sclerostin inhibitor, 210 mg subcutaneous monthly for 12 months) offers the unique advantage of building bone while reducing resorption simultaneously. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced new vertebral fractures by 48% versus alendronate alone [10]. Romosozumab carries a boxed warning for cardiovascular risk and requires careful patient selection.

Teriparatide (Forteo) or abaloparatide (Tymlos). These anabolic agents are options for patients with very high fracture risk. Coverage criteria are strict and typically require DXA T-scores below -3.0 or multiple fragility fractures, but they represent a legitimate avenue when Prolia is denied and bisphosphonates are contraindicated.

How to Start the Prolia Coverage Process at a Scripps Health Facility

The practical sequence a patient should follow when seeking Prolia through a Scripps Health-affiliated provider is straightforward. Schedule a visit with a Scripps rheumatologist or endocrinologist and bring all prior DXA reports. Ask the specialist to submit a prior-authorization request to your plan with complete documentation on the same day as the visit. Request the prior-authorization tracking number and check status with the plan after five business days.

If the authorization is not resolved within 10 business days and the clinical situation is urgent (recent fracture, ongoing bone loss), ask the physician to submit an expedited or urgent review request. Under federal law, Medicare Advantage plans must respond to urgent prior-authorization requests within 72 hours.

Patients should also ask the Scripps financial counseling team about 340B eligibility and Amgen patient assistance at the first appointment. Arranging financial support simultaneously with the authorization request prevents delays if the drug is approved before funding is confirmed.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states directly: "We recommend treatment with antiresorptive or anabolic agents for women with osteoporosis to reduce fracture risk, and denosumab is appropriate for patients who cannot use oral therapy or who have failed bisphosphonate treatment" [11]. That guideline language is exactly the kind of authoritative source physicians should attach to prior-authorization packets submitted to Scripps Health Plan or any other payer.

A FRAX calculation showing a 10-year major osteoporotic fracture probability above 20% or hip fracture probability above 3% meets the National Osteoporosis Foundation intervention threshold and strengthens any coverage appeal [12].